Olfactory Testing in Perinatal Asphyxia: Enhancing Risk Assessment

NCT ID: NCT06744244

Last Updated: 2024-12-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-09-10

Study Completion Date

2026-09-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Neonatal asphyxia remains a leading cause of neurodevelopmental disabilities despite advancements in perinatal care. Hypoxic-ischemic encephalopathy (HIE), a severe outcome of asphyxia, impacts 1-3 infants per 1,000 live births annually in industrialized nations, causing long-term neurological impairments such as cognitive dysfunction, motor deficits, and sensory impairments. Early identification of at-risk newborns is critical to initiate timely interventions and improve outcomes.

Olfactory perception, crucial for newborns' adaptation to extrauterine life, involves odor identification and memory. Odor perception is known to be impaired in adults with neurological disorders and in animal models of brain injury. However, no clinical studies have assessed olfactory function in newborns with signs of asphyxia. Olfactory memory, which can be evaluated through habituation to repeated odors, may provide insights into early brain function.

This study aims to evaluate whether olfactory memory can serve as an early marker of neurodevelopmental outcomes in newborns with signs of asphyxia. By assessing physiological, behavioral, and neurological responses to olfactory stimuli, the study seeks to explore the differences between infants with mild asphyxia and those with moderate-to-severe asphyxia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Neonatal asphyxia is the leading cause of neurodevelopmental disability. Despite recent advances in perinatal medicine, which have improved associated mortality, the neurological outcomes of hypoxic-ischemic events in newborns remain significant. The incidence of neonatal asphyxia is estimated to be 1.5 per 100 live births per year in industrialized countries with advanced obstetric-neonatal care. Between 1 and 3 infants per 1,000 live births suffer from severe neurological impairment due to perinatal asphyxia, developing hypoxic-ischemic encephalopathy.

Early identification of newborns with signs of asphyxia who are at high risk for hypoxic-ischemic encephalopathy and brain damage can improve outcomes by enabling the early initiation of rehabilitative interventions. Hypoxic-ischemic injury often results in impairments in audiovisual perception, cerebral palsy, cognitive dysfunction, memory difficulties, and other neurological sequelae.

Olfactory perception (the sense of smell) is one of the most important sensory functions in humans. In newborns, the sense of smell plays a crucial role, allowing them to perceive maternal odors and breast milk, guiding them in adapting to their environment and completing the physiological transition from intrauterine to extrauterine life. Olfactory neurosensory function involves several abilities, particularly odor identification and memory. Olfactory perception is also linked to olfactory memory, which can be tested as a habituation response. Olfactory memory is defined as the recollection of odorants. In recent studies, exposure to pleasant odors, such as breast milk or vanilla, has been shown to reduce perceived pain during invasive procedures in healthy full-term newborns. Olfactory stimuli can generate various physiological changes, regulating heart and respiratory rates, as well as triggering motor responses that guide head movements and initiate orofacial responses.

Some studies have shown that brain injury impairs odor perception: smell is altered in several neurological conditions, including both neurodevelopmental and neurodegenerative disorders. In Alzheimer (AD), Parkinson disease (PD) and in stroke, several cortical and subcortical areas directly involved in olfactory function are damaged or show signs of atrophy, including the olfactory bulb (OB), primary olfactory cortex (POC), hippocampus, orbitofrontal cortex (OFC), amygdala, and olfactory tract. Moreover, reduced odor detection early in life, along with anatomical and functional alterations in olfactory and higher-order cortical networks, has been reported in neurodevelopmental disorders such as Autistic Spectrum Disorder (ASD) and Attention Deficit / Hyperactivity Disorder (ADHD).

Olfactory dysfunction has also been studied and demonstrated in animal models through the induction of brain damage in rabbits. So far, no study has evaluated olfactory function in the clinical setting of brain injury due to neonatal asphyxia.

In cases of perinatal asphyxia, early identification of hypoxic-ischemic encephalopathy is achieved through continuous video-electroencephalographic monitoring, which is currently considered the gold standard for evaluating brain functions and detecting subclinical seizures. Although EEG does not directly assess olfactory function, certain electroencephalographic alterations may suggest impairment in brain regions involved in olfactory perception (piriform cortex, insular cortex, and amygdala).There are numerous studies in the literature that adopt various methods of olfactory testing in healthy newborns, but no validated tool or test exists to evaluate olfactory memory in newborns.

This study aims to assess olfactory function in newborns exhibiting signs of asphyxia at birth and to investigate whether infants with mild asphyxia differ from those with moderate to severe asphyxia.

The hypotheses of this study is that olfactory stimulation with odors such as rose, vanilla, and breast milk induces changes in heart rate, respiratory rate, peripheral oxygen saturation, EEG activity, and neuroimaging measures in asphyxiated newborns. These changes also occur following repeated olfactory stimuli. Olfactory memory, or habituation to odors, is delayed or absent in newborns with moderate-severe asphyxia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Birth Asphyxia Moderate Birth Asphyxia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Perinatal Asphyxia Hypoxic-Ischemic Encephalopathy Biomarkers Olfactory Function

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mild Birth Asphyxia

Term newborns (37-41 weeks of gestational age) with signs of moderate asphyxia at birth (cord pH \< 7.10 and/or BE \> -12), with mild asphyxia at birth.

Olfactory Testing

Intervention Type DIAGNOSTIC_TEST

Olfactory Test: Odor stimuli will be administered using a custom-designed olfactometer, developed by engineers specifically for this study. The olfactometer will release different odorants (maternal breast milk, vanilla essential oil, rose essential oil, and water as a control) in a controlled way. Each odor will be presented between 6 and 72 hours of life for 10 seconds (On), followed by a 50-second pause (Off) for a total of 15 cycles (On-Off). A new odor will be presented 5 minutes after the previous one. The first olfactory test will be conducted during the Video-EEG recording, and the second one will take place during the fMRI acquisition.

Heart rate (HR), Heart Rate Variability (HRV), Respiratory Rate (RR), peripheral oxygen saturation (SpO2)

Intervention Type DIAGNOSTIC_TEST

Simultaneously with the presentation of odors, heart rate (HR), heart rate variability (HRV), respiratory rate (RR), and peripheral oxygen saturation (SpO2) will be monitored and recorded. The onset of the odor will be recorded using a manual timer.

Video-EEG

Intervention Type DIAGNOSTIC_TEST

The infant's Video-EEG, as per guidelines following perinatal asphyxia, will be recorded for approximately 2 hours, including the period preceding odor administration (baseline).

fMRI

Intervention Type DIAGNOSTIC_TEST

Newborns will undergo an fMRI, as part of routine clinical practice, to identify any brain injury, its extent, and the structures involved. The use of a custom-built fMRI compatible olfactometer will facilitate these studies.

Neurodevelopment assessment

Intervention Type DIAGNOSTIC_TEST

Between 12 and 18 months, the infants will undergo neurodevelopmental follow-up, during which the Bayley III assessment will be administered to evaluate any potential neurocognitive deficits.

Moderate - Severe Birth Asphyxia

Term newborns (37-41 weeks of gestational age) with signs of moderate asphyxia at birth (cord pH \< 7.10 and/or BE \> -12) with moderate asphyxia at birth, at risk of developing hypoxic-ischemic encephalopathy, who don't need hypothermia treatment and with severe asphyxia at birth, at risk of developing hypoxic-ischemic encephalopathy who don't need hypothermia treatment.

Olfactory Testing

Intervention Type DIAGNOSTIC_TEST

Olfactory Test: Odor stimuli will be administered using a custom-designed olfactometer, developed by engineers specifically for this study. The olfactometer will release different odorants (maternal breast milk, vanilla essential oil, rose essential oil, and water as a control) in a controlled way. Each odor will be presented between 6 and 72 hours of life for 10 seconds (On), followed by a 50-second pause (Off) for a total of 15 cycles (On-Off). A new odor will be presented 5 minutes after the previous one. The first olfactory test will be conducted during the Video-EEG recording, and the second one will take place during the fMRI acquisition.

Heart rate (HR), Heart Rate Variability (HRV), Respiratory Rate (RR), peripheral oxygen saturation (SpO2)

Intervention Type DIAGNOSTIC_TEST

Simultaneously with the presentation of odors, heart rate (HR), heart rate variability (HRV), respiratory rate (RR), and peripheral oxygen saturation (SpO2) will be monitored and recorded. The onset of the odor will be recorded using a manual timer.

Video-EEG

Intervention Type DIAGNOSTIC_TEST

The infant's Video-EEG, as per guidelines following perinatal asphyxia, will be recorded for approximately 2 hours, including the period preceding odor administration (baseline).

fMRI

Intervention Type DIAGNOSTIC_TEST

Newborns will undergo an fMRI, as part of routine clinical practice, to identify any brain injury, its extent, and the structures involved. The use of a custom-built fMRI compatible olfactometer will facilitate these studies.

Neurodevelopment assessment

Intervention Type DIAGNOSTIC_TEST

Between 12 and 18 months, the infants will undergo neurodevelopmental follow-up, during which the Bayley III assessment will be administered to evaluate any potential neurocognitive deficits.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Olfactory Testing

Olfactory Test: Odor stimuli will be administered using a custom-designed olfactometer, developed by engineers specifically for this study. The olfactometer will release different odorants (maternal breast milk, vanilla essential oil, rose essential oil, and water as a control) in a controlled way. Each odor will be presented between 6 and 72 hours of life for 10 seconds (On), followed by a 50-second pause (Off) for a total of 15 cycles (On-Off). A new odor will be presented 5 minutes after the previous one. The first olfactory test will be conducted during the Video-EEG recording, and the second one will take place during the fMRI acquisition.

Intervention Type DIAGNOSTIC_TEST

Heart rate (HR), Heart Rate Variability (HRV), Respiratory Rate (RR), peripheral oxygen saturation (SpO2)

Simultaneously with the presentation of odors, heart rate (HR), heart rate variability (HRV), respiratory rate (RR), and peripheral oxygen saturation (SpO2) will be monitored and recorded. The onset of the odor will be recorded using a manual timer.

Intervention Type DIAGNOSTIC_TEST

Video-EEG

The infant's Video-EEG, as per guidelines following perinatal asphyxia, will be recorded for approximately 2 hours, including the period preceding odor administration (baseline).

Intervention Type DIAGNOSTIC_TEST

fMRI

Newborns will undergo an fMRI, as part of routine clinical practice, to identify any brain injury, its extent, and the structures involved. The use of a custom-built fMRI compatible olfactometer will facilitate these studies.

Intervention Type DIAGNOSTIC_TEST

Neurodevelopment assessment

Between 12 and 18 months, the infants will undergo neurodevelopmental follow-up, during which the Bayley III assessment will be administered to evaluate any potential neurocognitive deficits.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Term newborns (37-41 weeks of gestational age) with signs of asphyxia at birth (cord pH \< 7.10 and/or BE \> -12).
* Maternal age \> 18 years.
* No medication use during pregnancy (e.g., antipsychotics, antidepressants, sedatives, anticonvulsants, anxiolytics).
* Absence of maternal infections.
* Apgar score \< 5 at 10 minutes of life.
* Newborns with mild asphyxia at birth.
* Newborns with moderate asphyxia at birth, at risk of developing hypoxic-ischemic encephalopathy, who don't need hypothermia treatment.
* Newborns with severe asphyxia at birth, at risk of developing hypoxic-ischemic encephalopathy who don't need hypothermia treatment.

Exclusion Criteria

* Post-term infants (gestational age \> 42 weeks).
* Preterm infants (gestational age \< 37 weeks).
* Infants with genetic syndromes or congenital anomalies.
* Infants from mothers using drugs of abuse.
* Infants with scalp injuries or lesions.
* Infants with microcephaly.
* Infants who underwent therapeutic hypothermia.
Minimum Eligible Age

6 Hours

Maximum Eligible Age

72 Hours

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Azienda Ospedaliero-Universitaria di Parma

OTHER

Sponsor Role collaborator

University of Parma

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Serafina Perrone

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Serafina Perrone, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Università di Parma

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Azienda Ospedaliero-Universitaria di Parma

Parma, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Serafina Perrone, MD, PhD

Role: CONTACT

Phone: 3388704211

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Serafina Perrone, MD, PhD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Chavez-Valdez R, Miller S, Spahic H, Vaidya D, Parkinson C, Dietrick B, Brooks S, Gerner GJ, Tekes A, Graham EM, Northington FJ, Everett AD. Therapeutic Hypothermia Modulates the Relationships Between Indicators of Severity of Neonatal Hypoxic Ischemic Encephalopathy and Serum Biomarkers. Front Neurol. 2021 Nov 2;12:748150. doi: 10.3389/fneur.2021.748150. eCollection 2021.

Reference Type BACKGROUND
PMID: 34795631 (View on PubMed)

Finder M, Boylan GB, Twomey D, Ahearne C, Murray DM, Hallberg B. Two-Year Neurodevelopmental Outcomes After Mild Hypoxic Ischemic Encephalopathy in the Era of Therapeutic Hypothermia. JAMA Pediatr. 2020 Jan 1;174(1):48-55. doi: 10.1001/jamapediatrics.2019.4011.

Reference Type BACKGROUND
PMID: 31710357 (View on PubMed)

Ambalavanan N, Shankaran S, Laptook AR, Carper BA, Das A, Carlo WA, Cotten CM, Duncan AF, Higgins RD; EUNICE KENNEDY SHRIVER NICHD NEONATAL RESEARCH NETWORK. Early Determination of Prognosis in Neonatal Moderate or Severe Hypoxic-Ischemic Encephalopathy. Pediatrics. 2021 Jun;147(6):e2020048678. doi: 10.1542/peds.2020-048678. Epub 2021 May 13.

Reference Type BACKGROUND
PMID: 33986149 (View on PubMed)

Disdier C, Stonestreet BS. Hypoxic-ischemic-related cerebrovascular changes and potential therapeutic strategies in the neonatal brain. J Neurosci Res. 2020 Jul;98(7):1468-1484. doi: 10.1002/jnr.24590. Epub 2020 Feb 14.

Reference Type BACKGROUND
PMID: 32060970 (View on PubMed)

Drobyshevsky A, Robinson AM, Derrick M, Wyrwicz AM, Ji X, Englof I, Tan S. Sensory deficits and olfactory system injury detected by novel application of MEMRI in newborn rabbit after antenatal hypoxia-ischemia. Neuroimage. 2006 Sep;32(3):1106-12. doi: 10.1016/j.neuroimage.2006.06.002. Epub 2006 Jul 24.

Reference Type BACKGROUND
PMID: 16861007 (View on PubMed)

Juliano C, Sosunov S, Niatsetskaya Z, Isler JA, Utkina-Sosunova I, Jang I, Ratner V, Ten V. Mild intermittent hypoxemia in neonatal mice causes permanent neurofunctional deficit and white matter hypomyelination. Exp Neurol. 2015 Feb;264:33-42. doi: 10.1016/j.expneurol.2014.11.010. Epub 2014 Dec 2.

Reference Type BACKGROUND
PMID: 25476492 (View on PubMed)

Schaal B, Saxton TK, Loos H, Soussignan R, Durand K. Olfaction scaffolds the developing human from neonate to adolescent and beyond. Philos Trans R Soc Lond B Biol Sci. 2020 Jun 8;375(1800):20190261. doi: 10.1098/rstb.2019.0261. Epub 2020 Apr 20.

Reference Type BACKGROUND
PMID: 32306879 (View on PubMed)

Tristao RM, Lauand L, Costa KSF, Brant LA, Fernandes GM, Costa KN, Spilski J, Lachmann T. Olfactory sensory and perceptual evaluation in newborn infants: A systematic review. Dev Psychobiol. 2021 Nov;63(7):e22201. doi: 10.1002/dev.22201.

Reference Type BACKGROUND
PMID: 34674234 (View on PubMed)

Chen X, Gao F, Lin C, Chen A, Deng J, Chen P, Lin M, Xie B, Liao Y, Gong C, Zheng X. mTOR-mediated autophagy in the hippocampus is involved in perioperative neurocognitive disorders in diabetic rats. CNS Neurosci Ther. 2022 Apr;28(4):540-553. doi: 10.1111/cns.13762. Epub 2021 Nov 16.

Reference Type BACKGROUND
PMID: 34784444 (View on PubMed)

Lan HY, Yang L, Lin CH, Hsieh KH, Chang YC, Yin T. Breastmilk as a Multisensory Intervention for Relieving Pain during Newborn Screening Procedures: A Randomized Control Trial. Int J Environ Res Public Health. 2021 Dec 10;18(24):13023. doi: 10.3390/ijerph182413023.

Reference Type BACKGROUND
PMID: 34948633 (View on PubMed)

Baudesson de Chanville A, Brevaut-Malaty V, Garbi A, Tosello B, Baumstarck K, Gire C. Analgesic Effect of Maternal Human Milk Odor on Premature Neonates: A Randomized Controlled Trial. J Hum Lact. 2017 May;33(2):300-308. doi: 10.1177/0890334417693225. Epub 2017 Mar 27.

Reference Type BACKGROUND
PMID: 28346843 (View on PubMed)

Zhang S, Su F, Li J, Chen W. The Analgesic Effects of Maternal Milk Odor on Newborns: A Meta-Analysis. Breastfeed Med. 2018 Jun;13(5):327-334. doi: 10.1089/bfm.2017.0226. Epub 2018 May 7.

Reference Type BACKGROUND
PMID: 29733222 (View on PubMed)

Doucet S, Soussignan R, Sagot P, Schaal B. The "smellscape" of mother's breast: effects of odor masking and selective unmasking on neonatal arousal, oral, and visual responses. Dev Psychobiol. 2007 Mar;49(2):129-38. doi: 10.1002/dev.20210.

Reference Type BACKGROUND
PMID: 17299785 (View on PubMed)

Schaal B, Marlier L, Soussignan R. Responsiveness to the odour of amniotic fluid in the human neonate. Biol Neonate. 1995;67(6):397-406. doi: 10.1159/000244192.

Reference Type BACKGROUND
PMID: 7578623 (View on PubMed)

Schaal B, Marlier L, Soussignan R. Olfactory function in the human fetus: evidence from selective neonatal responsiveness to the odor of amniotic fluid. Behav Neurosci. 1998 Dec;112(6):1438-49. doi: 10.1037//0735-7044.112.6.1438.

Reference Type BACKGROUND
PMID: 9926826 (View on PubMed)

Schleidt M & Genzel C, The significance of mother's perfume for infants in the first weeks of their life. Ethology and Sociobiology. 1990; 11(3); 145-154. https://doi.org/10.1016/0162-3095(90)90007-S

Reference Type BACKGROUND

Varendi H, Christensson K, Porter RH, Winberg J. Soothing effect of amniotic fluid smell in newborn infants. Early Hum Dev. 1998 Apr 17;51(1):47-55. doi: 10.1016/s0378-3782(97)00082-0.

Reference Type BACKGROUND
PMID: 9570031 (View on PubMed)

Soussignan R, Schaal B, Marlier L. Olfactory alliesthesia in human neonates: prandial state and stimulus familiarity modulate facial and autonomic responses to milk odors. Dev Psychobiol. 1999 Jul;35(1):3-14. doi: 10.1002/(sici)1098-2302(199907)35:13.0.co;2-f.

Reference Type BACKGROUND
PMID: 10397891 (View on PubMed)

Soussignan R, Schaal B, Marlier L, Jiang T. Facial and autonomic responses to biological and artificial olfactory stimuli in human neonates: re-examining early hedonic discrimination of odors. Physiol Behav. 1997 Oct;62(4):745-58. doi: 10.1016/s0031-9384(97)00187-x.

Reference Type BACKGROUND
PMID: 9284493 (View on PubMed)

Bersani I, Piersigilli F, Gazzolo D, Campi F, Savarese I, Dotta A, Tamborrino PP, Auriti C, Di Mambro C. Heart rate variability as possible marker of brain damage in neonates with hypoxic ischemic encephalopathy: a systematic review. Eur J Pediatr. 2021 May;180(5):1335-1345. doi: 10.1007/s00431-020-03882-3. Epub 2020 Nov 27.

Reference Type BACKGROUND
PMID: 33245400 (View on PubMed)

Murray DM, Boylan GB, Ryan CA, Connolly S. Early EEG findings in hypoxic-ischemic encephalopathy predict outcomes at 2 years. Pediatrics. 2009 Sep;124(3):e459-67. doi: 10.1542/peds.2008-2190. Epub 2009 Aug 24.

Reference Type BACKGROUND
PMID: 19706569 (View on PubMed)

Allegaert K, van de Velde M, van den Anker J. Neonatal clinical pharmacology. Paediatr Anaesth. 2014 Jan;24(1):30-8. doi: 10.1111/pan.12176. Epub 2013 Apr 26.

Reference Type BACKGROUND
PMID: 23617305 (View on PubMed)

Boylan GB, Stevenson NJ, Vanhatalo S. Monitoring neonatal seizures. Semin Fetal Neonatal Med. 2013 Aug;18(4):202-8. doi: 10.1016/j.siny.2013.04.004. Epub 2013 May 24.

Reference Type BACKGROUND
PMID: 23707519 (View on PubMed)

Shellhaas RA, Soaita AI, Clancy RR. Sensitivity of amplitude-integrated electroencephalography for neonatal seizure detection. Pediatrics. 2007 Oct;120(4):770-7. doi: 10.1542/peds.2007-0514.

Reference Type BACKGROUND
PMID: 17908764 (View on PubMed)

Elshorbagy HH, Azab AA, Kamal NM, Barseem NF, Bassiouny MM, Elsayed MA, Elkhouly TH. Value of electroencephalographic monitoring in newborns with hypoxic-ischemic encephalopathy treated with hypothermia. J Pediatr Neurosci. 2016 Oct-Dec;11(4):309-315. doi: 10.4103/1817-1745.199467.

Reference Type BACKGROUND
PMID: 28217152 (View on PubMed)

Cloherty, J. P., Eichenwald, E. C., Stark, A. R., & Hansen, A. R. (Eds.). (2016). Cloherty and Stark's Manual of Neonatal Care (8th ed.). Philadelphia, PA: Wolters Kluwer.

Reference Type BACKGROUND

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

27408

Identifier Type: -

Identifier Source: org_study_id